Satralizumab for myelin oligodendrocyte glycoprotein antibody-associated disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 9 Mar 2022: Trial registered, NCT05271409
  2. 30 Aug 2022: Trial started, NCT05271409

The trials

NCT05271409: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

State
Under way
Phase
Phase 3
People
139 taking part
Started
30 Aug 2022
Primary completion
20 Nov 2025
Arms
Satralizumab
Results
None posted
  1. 9 Mar 2022: Trial registered
  2. 30 Aug 2022: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Recombinant Humanized Anti-Interleukin-6 Receptor Monoclonal Antibody Injection.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.